Vascular Biogenics Ltd. (NASDAQ:VBLT) was down 4% during mid-day trading on Friday . The company traded as low as $4.04 and last traded at $4.07, with a volume of 107,716 shares changing hands. The stock had previously closed at $4.24.

A number of equities research analysts have issued reports on VBLT shares. Zacks Investment Research lowered shares of Vascular Biogenics from a “hold” rating to a “sell” rating in a research note on Wednesday, June 22nd. Piper Jaffray Cos. reissued a “buy” rating and set a $14.00 target price on shares of Vascular Biogenics in a research note on Tuesday, June 7th. Chardan Capital reissued a “buy” rating on shares of Vascular Biogenics in a research note on Tuesday, June 7th. HC Wainwright started coverage on shares of Vascular Biogenics in a research note on Tuesday, June 28th. They set a “buy” rating and a $11.00 target price for the company. Finally, Roth Capital reissued a “buy” rating and set a $22.00 target price on shares of Vascular Biogenics in a research note on Thursday, June 9th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Vascular Biogenics has an average rating of “Buy” and a consensus price target of $13.67.

The stock’s 50 day moving average is $4.08 and its 200-day moving average is $3.74. The firm’s market capitalization is $96.06 million.

Vascular Biogenics (NASDAQ:VBLT) last posted its quarterly earnings results on Monday, August 15th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.09. On average, equities research analysts forecast that Vascular Biogenics Ltd. will post ($0.64) earnings per share for the current year.

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.